Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

Bristol Myers Squibb (BMY) is up more than +1% after gaining FDA approval for its Cobenfy drug to treat patients with schizophrenia. Amgen (AMGN) is up more than +1% after Cantor Fitzgerald initiated ...

The Dow Jones Industrial Average reached a record high following a modest inflation report, spurring hopes for additional ...

The blue-chip Dow Jones Industrial Average closed at a record high today as investors welcomed a subdued inflation report ...

U.S. stocks closed another record-setting week with a muted performance Friday, as hope built on Wall Street that the U.S. economy can manage the rare feat of suppressing high inflation without ...

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

The FDA has approved Bristol Myers Squibb’s new schizophrenia drug, Cobenfy, the first novel treatment for schizophrenia in ...

The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...

The Dow Jones Industrial Average edged up to another record high while declines in tech stocks pulled other indexes lower.

The Dow Jones Industrial Average closed at a record high, driven by investor optimism following a subdued inflation report.

In a breakthrough for people with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will be marketed under the name ...